Tim Oldham

Growing and transforming businesses in life and physical sciences and healthcare

[Tim Oldham @TimOldhamAU]

Catch @AdAlta1AD 's 11 May webinar on BZDS1901's potential to offer new hope for mesothelioma patients

[AdAlta Limited @AdAlta1AD]

BZSD1901 CAR-T: new hope for mesothelioma patients - webinar replay

BZDS1901 has already delivered impressive responses in clinical trials, including difficult to achieve complete tumour clearance. This webinar explores how this could transform mesothelioma outcomes

[Tim Oldham @TimOldhamAU]

@AdAlta1AD 's Entitlement Offer closing soon (5pm AEST Wednesday 28 May). Thank you to all who have supported the offer so far. Further details and recent webinar recording may be found on AdAlta's InvestorHub: https://t.co/kS5Hb5hoxY

[AdAlta Limited @AdAlta1AD]

AdAlta (ASX:1AD) is presenting at Peak Asset Management's Biotech Showcase on 21 August in Melbourne. Hear about our latest developments & investment insights from top advisors.

Space is limited, so register now for FREE! https://t.co/LK5TX0utTo

[AdAlta Limited @AdAlta1AD]

Join AdAlta’s CEO and Managing Director, Tim Oldham as he sits on an expert panel at the 2nd Australia Biologics Festival (20 Feb 2024) |
https://t.co/1Zc64GmcS9 #1AD @imapac #Biologics

[AdAlta Limited @AdAlta1AD]

Stockhead has released a special report on the countdown to AdAlta (ASX:1AD) trial results as biotech advances partner discussions. Read more here:
https://t.co/oKdubgXfHH @stockheadAU #1AD #Biotech #ASX

[Tim Oldham @TimOldhamAU]

@CarinaBiotech Congratulations @CarinaBiotech fro. Your collaborators at @AdAlta1AD

[Tim Oldham @TimOldhamAU]

@PeakAsset1 Another valuable brick in the safety profile for @AdAlta1AD’s #AD214

[AdAlta Limited @AdAlta1AD]

“It’s some of the coolest technology floating around in biotech today”.@TheMarketBullAU & @TimOldhamAU discuss AdAlta’s exciting progress & partnering opps for our i-body drug discovery platform; lead drug AD-214 for #fibrotic diseases & CAR-T cell therapy for cancer tumours.$1AD

[AdAlta Limited @AdAlta1AD]

@AdAlta1AD is pleased to invite shareholders/potential investors to a series of upcoming briefings at @AustSharesAssoc Investor Summit 2023 and in person. #1AD CEO & MD Dr @TimOldhamAU will discuss #AD214 and partnering. Register: https://t.co/0u3OMxfwyL $1AD #IPF

[Tim Oldham @TimOldhamAU]

Possibly our most important data this year so far …

[AdAlta Limited @AdAlta1AD]

@AdAlta1AD reports results of dose simulation studies, supporting efficacy of AD-214's target IV dose regimen. Also suggests that subcutaneous delivery could be effective & more convenient at a lower cost of goods, enhancing partnering potential. Results: https://t.co/rfEhNHfS4k

[AdAlta Limited @AdAlta1AD]

It's Pulmonary Fibrosis Awareness Month. As proud sponsors of double lung transplant recipient, Bill Van Nierop, @AdAlta1AD encourages you to support Bill's Long Kayak for Lungs 2, to raise $ for research & increase awareness of lung disease. https://t.co/ytsp6tVa5i

[AdAlta Limited @AdAlta1AD]

Fibrosis is a serious condition impacting millions globally. At @AdAlta1AD we’re working on new therapeutics to treat it. As part of Pulmonary Fibrosis Awareness Month, we look at fibrosis, its impacts & how we’re working to treat it. Read article: https://t.co/YhXNnlCxOR $1AD

[Tim Oldham @TimOldhamAU]

@CarinaBiotech Congratulations Leanna

[Tim Oldham @TimOldhamAU]

Sharing the ⁦@AdAlta1AD⁩ story at ⁦@PeakAsset1⁩ Microcap Conference today: new AD-214 data; partnering progress; blue sky transaction upside; oversubscribed shortfall placement

[Tim Oldham @TimOldhamAU]

A quick synopsis of the important data @AdAlta1AD released today

[AdAlta Limited @AdAlta1AD]

@AdAlta1AD (ASX: 1AD) CEO & MD Dr @TimOldhamAU talks to @proactive_au's Elisha Newell following today’s ASX announcement that new AD-214 data links preclinical animal & Phase I human results with efficacy & de-risks the Phase II dosing schedule. Watch:https://t.co/TqDIwLmjSy $1AD

[AdAlta Limited @AdAlta1AD]

Thanks those who saw @AdAlta1AD (ASX: 1AD) CEO @TimOldhamAU present at @TheCapNet's Emerging ASX Gems. Watch AdAlta at 17:40sec for an update on pipeline & the partnering opps flowing from data linking AD-214 preclinical animal studies & Phase I human results supporting efficacy

[Tim Oldham @TimOldhamAU]

Hard to over-estimate the significance of this data for @AdAlta1AD : AD-214 could be effective at clinically viable dosing regimens. De-risks clinical trials, enhances partnering

[AdAlta Limited @AdAlta1AD]

@AdAlta1AD (ASX: 1AD) today announced that new data for lead candidate AD-214 successfully links preclinical animal efficacy & Phase I human clinical trial results supporting & de-risking Phase II clinical dosing schedules for IPF, fibrotic diseases. Read: https://t.co/iO39M0NlW1

[Tim Oldham @TimOldhamAU]

Four days of high octane partnering at #BIO23 in Boston. Material progress on ⁦⁦@AdAlta1AD⁩ ‘s three partnering streams: out-licensing AD-214; partnering the i-body platform; and evaluating complimentary technologies and products. 48 meetings done. Best BIO yet.

[Tim Oldham @TimOldhamAU]

Great weekend at #ASCO23. Humbling to see the amazing minds and science being deployed to treat cancer. Exciting to gain new insights to ⁦@AdAlta1AD⁩ ‘s potential to contribute with our #ibody platform and i-CAR-T programs

[Tim Oldham @TimOldhamAU]

@AdAlta1AD 's capital raise is progressing well. Shortfall is covered but still a limited opportunity for qualified investors to participate: contact @PeakAsset1
https://t.co/vRN0YIR88P